Eyconis, Inc. is a privately held, pre-clinical stage biopharmaceutical company focused on transforming the ophthalmology treatment paradigm through the development, manufacture, and commercialization of novel, best-in-class therapeutics for eye diseases. The Company is advancing a pipeline of therapeutic candidates addressing areas of high unmet need including wet age-related macular degeneration (AMD). Eyconis is partnered with a syndicate of leading biopharma investors including Frazier Life Sciences, RA Capital Management, venBio Partners, and HealthQuest Capital. The Company is headquartered in Redwood City, California, including research & development laboratories with scientific and manufacturing team members.
Company Details
- Employees
- 35
- Founded
- -
- Address
- 1200 Bridge Pkwy,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.eyconis.com
- HQ
- Redwood City, California
Eyconis, Inc Questions
Eyconis, Inc's website is http://www.eyconis.com
Eyconis, Inc's LinkedIn profile is https://www.linkedin.com/company/eyconis-inc
Eyconis, Inc has
35 employees.
View email and phone details for 35
employees at Eyconis, Inc.
Eyconis, Inc's industry is
Biotechnology Research
Eyconis, Inc's top competitors are
Vaxcyte,
Adicet Bio, Inc,
Nurix Therapeutics,
Avenzo Therapeutics,
Ascendis Pharma,
Sionna Therapeutics,
Mirador Therapeutics,
Clasp Therapeutics,
Biomarin Pharmaceutical Inc.,
Janux Therapeutics.
Eyconis, Inc's categories are Biotechnology Research
Eyconis, Inc's founding year is 2024
